Seeking Alpha HealthcareOriginal article
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Phase 3DT-216P2Neutral
AI Analysis
Summary
Design Therapeutics plans to initiate registrational trial for DT-216P2 in Q4 2026 with 12-week results expected in Q1 2027.
Clinical Trial Data
Phase
3
Outcome Details
Registrational trial planned for Q4 2026 with 12-week results expected Q1 2027
Importance:5/10
Sentiment:
0.00
Phase 3registrationalDT-216P2clinical trial
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on October 4, 2026 2:08 PM